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Introduction
The volume of urological non-cancer surgery worldwide is large. In the UK alone, urologists plan more than 200 000 urological operations yearly [1] . Almost all patients undergoing such surgical procedures are at risk of deep vein thrombosis (DVT) and pulmonary embolism (PE)-together referred to as venous thromboembolism (VTE)-and major bleeding.
Whether to use thromboprophylaxis depends on the trade-off between a reduction in VTE and an increase in bleeding [2] . The benefits and harms of thromboprophylaxis critically depend on the risk of VTE and bleeding in those not receiving thromboprophylaxis, which we refer to as baseline risk. Prophylaxis is warranted when the baseline risk of VTE is high and the risk of bleeding is low, but not in those with low VTE risk and high bleeding risk.
Although the baseline risks of VTE and bleeding in the absence of prophylaxis vary widely between urological procedures [3, 4] , their specific magnitude has not been established. This uncertainty is, at least in part [4, 5] , responsible for substantial practice variation in the use of thromboprophylaxis in urology, both within and between countries [6] [7] [8] [9] . In an accompanying paper, we provide baseline risk estimates of VTE and bleeding for surgery in malignant diseases of the urinary tract and male genital system [7] . Here, we summarize the evidence regarding risks of VTE and bleeding in urological non-cancer surgery.
Evidence acquisition
Our study protocol, which was prospectively registered (PROSPERO: CRD42014010342) and previously published [2] , followed PRISMA guidance [10] . Our methods follow those presented in detail previously [2, 7] ; here, we summarize in brief.
Eligibility
We included observational studies published in English in which investigators enrolled at least 50 adult patients undergoing procedures for non-malignant diseases of the urinary tract or male genital system. Eligible studies reported absolute estimates of risk for one or more of the outcomes of interest: fatal PE, symptomatic PE, symptomatic DVT, symptomatic VTE, fatal bleeding, and bleeding requiring reoperation.
Data sources and searches
For the baseline risk of VTE and bleeding [2] , we conducted a comprehensive systematic search, developed together with experienced research librarians (N.B. and L.B.), of MEDLINE from January 1, 2000 to January 1, 2016 (Supplementary material, pages 58-63). We performed additional searches:
(1) for patient-related risk factors for VTE and bleeding after surgery; (2) for cohort studies addressing timing of VTE and bleeding after surgery to inform modeling of outcomes for studies with varying follow-up; and (3) for randomized trials addressing the effects of pharmacological and mechanical thromboprophylaxis on VTE and bleeding risk after surgery to calculate baseline risks in patients not receiving prophylaxis (Supplementary material, pages 64-68).
Study selection and data abstraction
We used standard methods for systematic reviews for independent duplicate screening and data extraction [2, 7] . To confirm the accuracy of the data extracted, and if necessary to clarify missing or unclear information, we contacted the authors of all the original articles.
Risk of bias
Through iterative discussion and consensus-building, and informed by the prior literature [11, 12] , we developed a novel instrument to categorize studies as either at low or high risk of bias (RoB) in their estimates of VTE or bleeding risk [2, 7] . Items included the representativeness of the patient population, thromboprophylaxis documentation, data sources, whether a majority of patient recruitment years were earlier or later than 2000, clear specification of the duration of follow-up, and study type (Supplementary material, page 17).
Analysis
Outcomes
Outcomes included the absolute risks of symptomatic VTE and bleeding requiring reoperation (including exploration and angioembolization) at 4 wk, as well as fatal PE and fatal bleeding. We analyzed all outcomes separately for each type of procedure.
Calculating the risk of VTE and bleeding for individual studies
In calculating VTE and bleeding risk, we adjusted analyses for the extent of thromboprophylaxis use (Supplementary material, pages 27-28, 30, 34-57), as described in an accompanying paper. For studies that did not report on use of thromboprophylaxis, we estimated thromboprophylaxis use (Supplementary material, page 29).
Choosing the best estimates
We used the median value of estimates from eligible studies to estimate baseline risk of VTE and bleeding requiring reoperation [2] .
Patient summary: The best evidence suggests that the benefits of blood-thinning drugs to prevent clots after surgery outweigh the risks of bleeding in some procedures (such as kidney transplantation procedures in patients at high risk of clots) but not others (such as prostate surgery in patients at low risk of clots 
Risk stratification
After assessing the baseline risk of VTE for each procedure, we estimated risk for groups of patients according to patient risk factors (Table 1 ; Supplementary material, pages 31-33, 36-37) [2,7].
Quality of evidence
We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) to rate the quality of evidence (also known as certainty or confidence in evidence) [7, 13, 14] . The quality of a body of evidence drawn from observational studies addressing a question of prognosis begins as ''high quality''; in all cases, we rated down to ''moderate quality'' because of uncertainties in our modeling of the risks of VTE and bleeding over time (Supplementary material, pages 34-35) and in our model of patient risk strata (Table 1) [2, 7] . Whenever identified, we further rated down for RoB, inconsistency of results, indirectness of evidence, or imprecision [7] .
Evidence synthesis
3. Table 2 ). On the basis of these studies, we created seven evidence profiles of the risks of VTE and bleeding and four evidence profiles without information on bleeding (Supplementary material, pages [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Of the 38 primary study authors contacted, 22 (58%) confirmed the accuracy of our data extraction, corrected errors, and/or provided additional information (Supplementary material, page 72).
3.2.
Study characteristics and quality of evidence Table 2 presents the characteristics of the studies for each procedure (more details are available in the Supplementary material, pages [14] [15] [16] . The median of the mean/median ages varied from 47 yr for donor and recipient nephrectomies to 71 yr for TURP or its equivalent ( Table 2) . Eligible studies included two low RoB and 17 high RoB studies for (Table 3 and Supplementary material, pages 3-13).
Thromboprophylaxis use
Most open recipient nephrectomy (80%), open prolapse surgery (67%), and TURP (67%) studies reported information on the use of thromboprophylaxis; rates of reporting of thromboprophylaxis use were lower for other procedures (median 0%, interquartile range [IQR] 0-40%; Table 2 ).
Among the studies providing this information, short duration was reported for PCNL, open prolapse surgery, and reconstructive pelvic surgery (median 1.0 d, IQR 0-1.3), longer for laparoscopic donor nephrectomies (median 3.4 d, IQR 2.0-9.1), and longest for open recipient nephrectomy 
Discussion
This systematic review provides the first summary of best estimates of the baseline risk of symptomatic VTE and serious bleeding for major non-cancer surgeries in urology. Among urological non-cancer procedures for which we were able to estimate both VTE and bleeding risks, the highest baseline risk of VTE at 4 wk was observed for open recipient nephrectomy (1.3-5.3%), for which the risk varied with patient factors (age, BMI, and personal or family history of VTE; Table 3 ). Patients undergoing donor nephrectomy were at lower risk of VTE than those undergoing recipient nephrectomy (range 0.4-1.4% for laparoscopic and 0.3-1.3% for open surgery across risk groups). The risk of VTE was <1.0% for all risk groups after TURP, open prolapse surgery, reconstructive pelvic surgery, and PCNL (Table 3) . Among urological non-cancer procedures, studies on open recipient nephrectomy reported the highest baseline risk of bleeding requiring reoperation at 4 wk (2.4%), followed by studies on PCNL (0.9%). The risk of bleeding requiring reoperation was 0.5% for all other non-cancer procedures. Certainty for both VTE and bleeding estimates was either low or very low (Table 3 ).
Strengths and limitations
The strengths of our study include a contemporary and procedure-specific search; rigorous adherence to methodological standards, including duplicate assessment of eligibility and data abstraction, and checking of abstracted data by a methodologist clinician; systematic appraisal of RoB; and assessment of the quality of evidence using the GRADE system [13, 14] . Successful communication with many of the authors of the studies included provided far more complete data than the original publications alone. To optimize the applicability to current practice, we used only studies in which all patients underwent surgery in 1990 or thereafter. We developed novel methods for constructing models for estimation that considered the length of followup, the use of thromboprophylaxis, and patient risk factors [2, 7] . The limitations of our review are largely those of the original studies. Many studies did not provide information regarding the use of thromboprophylaxis or the precise length of follow-up [15] [16] [17] . Studies were generally at high risk of bias; the modeling approaches-including assumptions for thromboprophylaxis use-we needed to use are associated with unavoidable uncertainty, and estimates were often associated with substantial imprecision [7] . As a result, we categorized the evidence as low or very low in quality, reducing the strength of inferences that can be drawn from the evidence.
Clinical implications
These summaries should have important implications for the practice of urological surgery worldwide. Both anecdotally and in the formal comparisons undertaken, post-discharge thromboprophylaxis practice varies widely both within and between countries. Our results were consistent with this evidence: we found that there was very large variation in the use of thromboprophylaxis across studies [6] [7] [8] .
When estimates clearly suggest that the benefits of VTE prevention outweigh over risks of bleeding (ie, for all types of kidney transplantation procedure in high-risk patients), or conversely when estimates clearly show that bleeding risks outweigh any benefit from thromboprophylaxis (ie, in TURP, PCNL and reconstructive female pelvic surgery in low-risk patients) such variation is problematic. When the trade-off is closer ([ 1 4 _ T D $ D I F F ] for [ 1 5 _ T D $ D I F F ] instance, open prolapse surgery in high-risk patients), evaluation of the benefits versus risks of thromboprophylaxis will differ across surgeons and patients, and one would expect practice to vary.
Our work highlights that in non-cancer urology the evidence is of low or very low quality, even for procedures with high volumes and non-negligible risks, including kidney transplantation and TURP. Therefore, the generation of higher-quality evidence should constitute a research priority. This research should adhere to methodological standards that have seldom been observed thus far, including comprehensive characterization of patient populations and follow-up times, documentation of prophylaxis use, and reproducible measurements of DVT, PE, and bleeding. Studies on the importance that patients place on avoiding VTE versus avoiding bleeding would further enhance optimal decision-making regarding thromboprophylaxis for urological procedures.
Conclusions
The current evidence suggests a net benefit of VTE prophylaxis for some procedures (kidney transplantation procedures in high-risk patients) but that bleeding risks outweigh the benefits of thromboprophylaxis (net harm) for others (TURP and reconstructive female pelvic surgery in low-risk patients). The evidence regarding the baseline risk of VTE and bleeding in non-cancer urology is of low or very low quality; generating higher-quality evidence should constitute a research priority. Statistical analysis: Tikkinen, Craigie, Guyatt.
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